annual FCF:
$239.25M+$294.18M(+535.61%)Summary
- As of today (September 10, 2025), CPRX annual free cash flow is $239.25 million, with the most recent change of +$294.18 million (+535.61%) on December 31, 2024.
- During the last 3 years, CPRX annual FCF has risen by +$179.90 million (+303.11%).
- CPRX annual FCF is now at all-time high.
Performance
CPRX Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
$71.27M+$11.23M(+18.70%)Summary
- As of today (September 10, 2025), CPRX quarterly free cash flow is $71.27 million, with the most recent change of +$11.23 million (+18.70%) on June 30, 2025.
- Over the past year, CPRX quarterly FCF has increased by +$7.15 million (+11.15%).
- CPRX quarterly FCF is now -1.85% below its all-time high of $72.61 million, reached on September 30, 2024.
Performance
CPRX quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$274.72M+$7.15M(+2.67%)Summary
- As of today (September 10, 2025), CPRX TTM free cash flow is $274.72 million, with the most recent change of +$7.15 million (+2.67%) on June 30, 2025.
- Over the past year, CPRX TTM FCF has increased by +$114.25 million (+71.19%).
- CPRX TTM FCF is now at all-time high.
Performance
CPRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
CPRX Free cash flow Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +535.6% | +11.2% | +71.2% |
3 y3 years | +303.1% | +172.4% | +264.3% |
5 y5 years | +591.6% | +437.3% | +460.3% |
CPRX Free cash flow Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +535.6% | -1.9% | +147.4% | at high | +600.2% |
5 y | 5-year | at high | +535.6% | -1.9% | +147.4% | at high | +600.2% |
alltime | all time | at high | +535.6% | -1.9% | +147.4% | at high | +600.2% |
CPRX Free cash flow History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | $71.27M(+18.7%) | $274.72M(+2.7%) |
Mar 2025 | - | $60.04M(-15.2%) | $267.57M(+11.8%) |
Dec 2024 | $239.25M(-535.6%) | $70.79M(-2.5%) | $239.25M(+27.2%) |
Sep 2024 | - | $72.61M(+13.2%) | $188.02M(+17.2%) |
Jun 2024 | - | $64.13M(+102.1%) | $160.47M(+26.3%) |
Mar 2024 | - | $31.73M(+62.2%) | $127.10M(-331.4%) |
Dec 2023 | -$54.92M(-151.8%) | $19.55M(-56.6%) | -$54.92M(+59.7%) |
Sep 2023 | - | $45.06M(+46.5%) | -$34.40M(-28.6%) |
Jun 2023 | - | $30.75M(-120.5%) | -$48.16M(-8.7%) |
Mar 2023 | - | -$150.30M(-475.0%) | -$52.76M(-149.8%) |
Dec 2022 | $106.02M(+78.6%) | $40.08M(+28.0%) | $106.02M(+24.6%) |
Sep 2022 | - | $31.30M(+19.6%) | $85.08M(+12.8%) |
Jun 2022 | - | $26.16M(+208.6%) | $75.41M(+16.2%) |
Mar 2022 | - | $8.48M(-55.7%) | $64.93M(+9.4%) |
Dec 2021 | $59.35M(+31.8%) | $19.14M(-11.6%) | $59.35M(+11.3%) |
Sep 2021 | - | $21.64M(+38.1%) | $53.32M(+23.7%) |
Jun 2021 | - | $15.67M(+439.9%) | $43.12M(+5.9%) |
Mar 2021 | - | $2.90M(-77.8%) | $40.71M(-9.6%) |
Dec 2020 | $45.02M(+30.2%) | $13.11M(+14.6%) | $45.02M(+1.8%) |
Sep 2020 | - | $11.44M(-13.8%) | $44.21M(-9.8%) |
Jun 2020 | - | $13.27M(+83.9%) | $49.03M(-1.5%) |
Mar 2020 | - | $7.21M(-41.3%) | $49.77M(+43.9%) |
Dec 2019 | $34.59M(-234.1%) | $12.29M(-24.4%) | $34.59M(+148.3%) |
Sep 2019 | - | $16.26M(+16.1%) | $13.93M(-252.1%) |
Jun 2019 | - | $14.01M(-275.8%) | -$9.16M(-66.9%) |
Mar 2019 | - | -$7.97M(-4.8%) | -$27.68M(+7.3%) |
Dec 2018 | -$25.80M(+87.7%) | -$8.37M(+22.6%) | -$25.80M(+20.2%) |
Sep 2018 | - | -$6.83M(+51.1%) | -$21.46M(+24.3%) |
Jun 2018 | - | -$4.52M(-25.7%) | -$17.26M(+8.3%) |
Mar 2018 | - | -$6.08M(+50.9%) | -$15.95M(+16.0%) |
Dec 2017 | -$13.74M(-23.9%) | -$4.03M(+53.1%) | -$13.74M(-2.8%) |
Sep 2017 | - | -$2.63M(-17.8%) | -$14.13M(-4.4%) |
Jun 2017 | - | -$3.20M(-17.5%) | -$14.78M(-7.7%) |
Mar 2017 | - | -$3.88M(-12.2%) | -$16.01M(-11.4%) |
Dec 2016 | -$18.06M(+0.1%) | -$4.42M(+34.8%) | -$18.06M(-1.2%) |
Sep 2016 | - | -$3.28M(-26.0%) | -$18.27M(-10.2%) |
Jun 2016 | - | -$4.43M(-25.3%) | -$20.35M(+0.9%) |
Mar 2016 | - | -$5.93M(+28.0%) | -$20.17M(+11.8%) |
Dec 2015 | -$18.04M | -$4.63M(-13.6%) | -$18.04M(+3.7%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2015 | - | -$5.36M(+26.2%) | -$17.40M(+11.5%) |
Jun 2015 | - | -$4.25M(+11.7%) | -$15.61M(+8.7%) |
Mar 2015 | - | -$3.80M(-4.8%) | -$14.36M(+10.5%) |
Dec 2014 | -$13.00M(+31.5%) | -$3.99M(+12.0%) | -$13.00M(-1.0%) |
Sep 2014 | - | -$3.57M(+19.0%) | -$13.14M(+16.7%) |
Jun 2014 | - | -$3.00M(+22.7%) | -$11.25M(+11.8%) |
Mar 2014 | - | -$2.44M(-40.9%) | -$10.07M(+1.9%) |
Dec 2013 | -$9.89M(+90.4%) | -$4.13M(+145.3%) | -$9.89M(+33.7%) |
Sep 2013 | - | -$1.68M(-7.1%) | -$7.39M(+8.6%) |
Jun 2013 | - | -$1.81M(-19.8%) | -$6.81M(+10.8%) |
Mar 2013 | - | -$2.26M(+37.8%) | -$6.15M(+18.3%) |
Dec 2012 | -$5.19M(+4.1%) | -$1.64M(+48.9%) | -$5.19M(+4.0%) |
Sep 2012 | - | -$1.10M(-4.0%) | -$4.99M(-2.9%) |
Jun 2012 | - | -$1.15M(-12.2%) | -$5.15M(-5.8%) |
Mar 2012 | - | -$1.31M(-9.3%) | -$5.46M(+9.5%) |
Dec 2011 | -$4.99M(+32.7%) | -$1.44M(+15.0%) | -$4.99M(+15.5%) |
Sep 2011 | - | -$1.25M(-14.5%) | -$4.32M(+11.2%) |
Jun 2011 | - | -$1.46M(+76.3%) | -$3.89M(+8.8%) |
Mar 2011 | - | -$831.10K(+7.6%) | -$3.57M(-5.1%) |
Dec 2010 | -$3.76M(-51.1%) | -$772.10K(-5.5%) | -$3.76M(-1.5%) |
Sep 2010 | - | -$817.30K(-28.9%) | -$3.82M(-12.3%) |
Jun 2010 | - | -$1.15M(+12.5%) | -$4.36M(-25.8%) |
Mar 2010 | - | -$1.02M(+22.9%) | -$5.87M(-23.6%) |
Dec 2009 | -$7.69M(-7.0%) | -$831.20K(-38.6%) | -$7.69M(-21.2%) |
Sep 2009 | - | -$1.35M(-49.2%) | -$9.75M(-10.7%) |
Jun 2009 | - | -$2.66M(-6.1%) | -$10.92M(+10.6%) |
Mar 2009 | - | -$2.84M(-2.2%) | -$9.87M(+19.5%) |
Dec 2008 | -$8.26M(+84.0%) | -$2.90M(+15.1%) | -$8.26M(+31.1%) |
Sep 2008 | - | -$2.52M(+56.0%) | -$6.30M(+40.2%) |
Jun 2008 | - | -$1.62M(+31.8%) | -$4.50M(+3.5%) |
Mar 2008 | - | -$1.23M(+30.0%) | -$4.35M(-3.2%) |
Dec 2007 | -$4.49M(+274.4%) | -$942.20K(+32.0%) | -$4.49M(+6.2%) |
Sep 2007 | - | -$714.00K(-51.3%) | -$4.23M(+17.8%) |
Jun 2007 | - | -$1.46M(+6.9%) | -$3.59M(+69.0%) |
Mar 2007 | - | -$1.37M(+101.8%) | -$2.12M(+182.0%) |
Dec 2006 | -$1.20M(+161.2%) | -$678.90K(+819.9%) | -$752.70K(+919.9%) |
Sep 2006 | - | -$73.80K | -$73.80K |
Dec 2005 | -$459.30K(+97.7%) | - | - |
Dec 2004 | -$232.30K(-36.5%) | - | - |
Dec 2003 | -$365.80K | - | - |
FAQ
- What is Catalyst Pharmaceuticals, Inc. annual free cash flow?
- What is the all time high annual FCF for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. annual FCF year-on-year change?
- What is Catalyst Pharmaceuticals, Inc. quarterly free cash flow?
- What is the all time high quarterly FCF for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. quarterly FCF year-on-year change?
- What is Catalyst Pharmaceuticals, Inc. TTM free cash flow?
- What is the all time high TTM FCF for Catalyst Pharmaceuticals, Inc.?
- What is Catalyst Pharmaceuticals, Inc. TTM FCF year-on-year change?
What is Catalyst Pharmaceuticals, Inc. annual free cash flow?
The current annual FCF of CPRX is $239.25M
What is the all time high annual FCF for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high annual free cash flow is $239.25M
What is Catalyst Pharmaceuticals, Inc. annual FCF year-on-year change?
Over the past year, CPRX annual free cash flow has changed by +$294.18M (+535.61%)
What is Catalyst Pharmaceuticals, Inc. quarterly free cash flow?
The current quarterly FCF of CPRX is $71.27M
What is the all time high quarterly FCF for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high quarterly free cash flow is $72.61M
What is Catalyst Pharmaceuticals, Inc. quarterly FCF year-on-year change?
Over the past year, CPRX quarterly free cash flow has changed by +$7.15M (+11.15%)
What is Catalyst Pharmaceuticals, Inc. TTM free cash flow?
The current TTM FCF of CPRX is $274.72M
What is the all time high TTM FCF for Catalyst Pharmaceuticals, Inc.?
Catalyst Pharmaceuticals, Inc. all-time high TTM free cash flow is $274.72M
What is Catalyst Pharmaceuticals, Inc. TTM FCF year-on-year change?
Over the past year, CPRX TTM free cash flow has changed by +$114.25M (+71.19%)